Shionogi’s XOCOVA® Becomes First FDA-Approved Oral Treatment for Preventing COVID-19 Following Exposure Shionogi & Co., Ltd. has announced a significant regulatory milestone for its antiviral medicine XOCOVA® (ensitrelvir), with the…
Avenzo Reports Updated Phase 1 Data for AVZO-021 Showing Clinical Activity and Favorable Tolerability in Heavily Pretreated HR+/HER2- Breast Cancer Avenzo Therapeutics has announced updated clinical findings from the Phase…
Rallybio and Avenzo Therapeutics Announce Merger Backed by $215 Million Financing to Advance Next-Generation Oncology Pipeline Rallybio Corporation and Avenzo Therapeutics have entered into a definitive merger agreement that will…
Novel Blood Test Reveals Key Tumor Microenvironment Signals Predictive of Immunotherapy Outcomes in Sarcoma Aqtual, Inc., a precision medicine company focused on developing advanced cell-free DNA (cfDNA) diagnostics for oncology…
Qurient Doses First Patient in Phase 2 Trial of Mocaciclib for CDK4/6 Inhibitor-Resistant HR-Positive Breast Cancer Qurient Co., Ltd. has announced a major clinical development milestone with the dosing of…
Sumitomo Pharma America Reports Promising Early Clinical Results for Investigational CHK1 Inhibitor SMP-3124LP in Advanced Solid Tumors Sumitomo Pharma America, Inc. (SMPA) has unveiled encouraging clinical findings from its ongoing…
Vertex’s Biologics License Application for Povetacicept Accepted by FDA, Advancing Potential New Treatment for IgA Nephropathy Vertex Pharmaceuticals has reached an important regulatory milestone in its efforts to expand into…
Teleflex Launches $500 Million Senior Notes Offering to Support Debt Refinancing Strategy Teleflex Incorporated has announced the launch of a private offering of $500 million in aggregate principal amount of…
FDA Approves FoundationOne CDx Tests as Companion Diagnostics for TALZENNA and XTANDI in HRR Gene–Mutated Metastatic Castration-Resistant Prostate Cancer Foundation Medicine, a global precision medicine company dedicated to advancing personalized…
Lysoway Therapeutics Secures Additional MJFF Funding to Advance TMEM175 Agonist Program for Parkinson’s Disease Lysoway Therapeutics, a biopharmaceutical company focused on developing small-molecule therapies that target lysosomal ion channels, has…
Corcept Therapeutics Reports Statistically Significant Overall Survival Benefit for Lifyorli in Platinum-Resistant Ovarian Cancer at ASCO 2026 Corcept Therapeutics Incorporated, a commercial-stage biopharmaceutical company focused on discovering and developing therapies…
Veracyte’s Prosigna Test Shows Practice-Changing Results in Early Breast Cancer at ASCO 2026 OPTIMA Trial Veracyte, Inc., a leading cancer diagnostics company, has announced highly significant results from the independent…